Security
Mast Therapeutics, Inc. Warrants Expiring 11/16/2016 · MTPSW
MTPSWOTCWarrantHistorical · closed Nov 14, 2016CIK 1160308Updated Nov 17, 2026
MTPSW price & chart
This listing closed Nov 14, 2016. Live provider charts are shown only for current listings.
Current security: SVRA
About the company
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Savara’s lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Savara’s management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
S-8 filing
10-Q filing
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 140,924,000Source | 238,817,000Source | 192,138,000Source | 163,765,000Source | 139,670,000Source | 221,645,000Source | 189,316,000Source | 158,295,000Source | 253,436,000Source | 212,879,000Source | 177,564,000Source | 139,777,000Source |
| Property, Plant and Equipment, NetUSD | 85,000Source | 206,000Source | 641,000Source | 119,000Source | 236,000Source | 130,000Source | 138,000Source | 248,000Source | 100,000Source | 165,000Source | 270,000Source | 51,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,277,000Source | 21,427,000Source | 41,800,000Source | 17,436,000Source | 23,864,000Source | 38,791,000Source | 19,556,000Source | 16,785,000Source | 33,180,000Source | 15,128,000Source | 26,585,000Source | 52,100,000Source |
| Assets, CurrentUSD | 128,198,000Source | 226,395,000Source | 178,317,000Source | 150,988,000Source | 127,694,000Source | 209,265,000Source | 177,444,000Source | 146,187,000Source | 241,616,000Source | 202,135,000Source | 165,947,000Source | 128,954,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,812,000Source | 6,955,000Source | 5,283,000Source | 4,545,000Source | 6,178,000Source | 6,493,000Source | 4,944,000Source | 3,144,000Source | 5,914,000Source | 5,808,000Source | 3,628,000Source | 3,078,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 100,000Source | 200,000Source | 400,000Source | 100,000Source |
| Other Assets, NoncurrentUSD | 990,000Source | 1,105,000Source | 1,891,000Source | 1,029,000Source | 1,106,000Source | 886,000Source | 1,001,000Source | 1,148,000Source | 84,000Source | 242,000Source | 387,000Source | 116,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 46,538,000Source | 39,468,000Source | 48,478,000Source | 43,281,000Source | 37,939,000Source | 45,606,000Source | 41,466,000Source | 36,434,000Source | 50,303,000Source | 41,430,000Source | 37,192,000Source | 31,999,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 173,000Source | 172,000Source | 204,000Source | 173,000Source | 140,000Source | 204,000Source | 173,000Source | 140,000Source | 204,000Source | 173,000Source | 140,000Source | 116,000Source |
| Retained Earnings (Accumulated Deficit)USD | -575,851,000Source | -460,206,000Source | -685,599,000Source | -546,290,000Source | -435,958,000Source | -645,371,000Source | -515,889,000Source | -413,715,000Source | -608,087,000Source | -489,250,000Source | -393,369,000Source | -338,671,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -155,000Source | 299,000Source | -534,000Source | -216,000Source | -880,000Source | -429,000Source | -632,000Source | -742,000Source | -87,000Source | -750,000Source | -271,000Source | -605,000Source |
| Stockholders' Equity Attributable to ParentUSD | 94,386,000Source | 199,349,000Source | 143,660,000Source | 120,484,000Source | 101,731,000Source | 176,039,000Source | 147,850,000Source | 121,861,000Source | 203,133,000Source | 171,449,000Source | 140,372,000Source | 107,778,000Source |
| Additional Paid in Capital, Common StockUSD | 670,219,000Source | 659,084,000Source | 829,589,000Source | 666,817,000Source | 538,429,000Source | 821,635,000Source | 664,198,000Source | 536,178,000Source | 811,103,000Source | 661,276,000Source | 533,872,000Source | 446,938,000Source |
| Liabilities and EquityUSD | 140,924,000Source | 238,817,000Source | 192,138,000Source | 163,765,000Source | 139,670,000Source | 221,645,000Source | 189,316,000Source | 158,295,000Source | 253,436,000Source | 212,879,000Source | 177,564,000Source | 139,777,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 16,757,000Source | 12,788,000Source | 17,599,000Source | 13,628,000Source | 11,286,000Source | 15,539,000Source | 11,898,000Source | 9,810,000Source | 20,396,000Source | 14,724,000Source | 10,597,000Source | 5,867,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | 200,000Source | 200,000Source | 60,000Source |
| Accounts Payable, CurrentUSD | 4,136,000Source | 4,609,000Source | 7,000,000Source | 4,749,000Source | 3,386,000Source | 4,496,000Source | 5,557,000Source | 2,853,000Source | 5,757,000Source | 4,545,000Source | 3,504,000Source | 1,334,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | 100,000Source | 200,000Source | 50,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 128,000Source | 770,000Source | 0Source | 169,000Source | — | 44,000Source | 208,000Source | 0Source | 87,000Source | 247,000Source | 54,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 12,621,000Source | 8,179,000Source | 10,599,000Source | 8,879,000Source | 7,900,000Source | 11,043,000Source | 6,341,000Source | 6,957,000Source | 14,639,000Source | 10,179,000Source | 7,093,000Source | 4,533,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 29,781,000Source | 26,552,000Source | 30,109,000Source | 29,653,000Source | 26,484,000Source | 30,067,000Source | 29,524,000Source | 26,416,000Source | 29,907,000Source | 26,619,000Source | 26,348,000Source | 26,078,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 29,781,000Source | 26,552,000Source | 30,109,000Source | 29,653,000Source | 26,484,000Source | 30,067,000Source | 29,524,000Source | 26,416,000Source | 29,907,000Source | 26,619,000Source | 26,348,000Source | 26,078,000Source |
| Short-term InvestmentsUSD | 108,109,000Source | 198,013,000Source | 131,234,000Source | 129,007,000Source | 97,652,000Source | 163,981,000Source | 152,944,000Source | 126,258,000Source | 202,522,000Source | 181,199,000Source | 135,734,000Source | 73,776,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -37,284,000Source | -26,639,000Source | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,727,000Source | 2,972,000Source | 14,421,000Source | 9,860,000Source | 4,178,000Source | 2,041,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -33,046,000Source | -27,189,000Source | -101,037,000Source | -89,088,000Source | -51,061,000Source | -34,554,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 38,778,000Source | 29,329,000Source | -18,440,000Source | -39,941,000Source | -57,116,000Source | 52,645,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 54,000Source | 3,000Source | 22,000Source | 25,000Source | 296,000Source | 9,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -195,000Source | 2,318,000Source | 137,806,000Source | 117,577,000Source | 82,780,000Source | 87,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | 27,230,000Source | 27,229,000Source | — | — | 26,350,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 5,611,000Source | 4,428,000Source | 18,052,000Source | -11,457,000Source | -25,515,000Source | 18,088,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 617,000Source | 1,325,000Source | 3,201,000Source | 2,124,000Source | 2,040,000Source | 1,614,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,425,000Source | 2,371,000Source | 7,765,000Source | 2,669,000Source | 10,727,000Source | 2,972,000Source | 14,421,000Source | 9,860,000Source | 4,178,000Source | 2,041,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 160,000Source | 70,000Source | 453,000Source | 271,000Source | 271,000Source | 334,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 146,000Source | -20,000Source | -81,000Source | 118,000Source | -216,000Source | 60,000Source | 310,000Source | 51,000Source | 76,000Source | -19,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | -546,000Source | -546,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 9,627,000Source | 6,013,000Source | 18,986,000Source | 10,655,000Source | 15,568,000Source | 9,246,000Source | 42,056,000Source | 25,037,000Source | 15,668,000Source | 10,929,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 9,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,561,000Source | -24,248,000Source | -40,228,000Source | -30,401,000Source | -37,284,000Source | -26,639,000Source | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -29,561,000Source | -24,248,000Source | -40,228,000Source | -30,401,000Source | -37,284,000Source | -26,639,000Source | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Operating ExpensesUSD | — | — | 30,255,000Source | 26,357,000Source | 40,965,000Source | 31,440,000Source | 38,990,000Source | 28,435,000Source | 123,547,000Source | 103,196,000Source | 60,007,000Source | 38,839,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 694,000Source | 2,109,000Source | 737,000Source | 1,039,000Source | 1,706,000Source | 1,796,000Source | 4,710,000Source | 7,315,000Source | 5,309,000Source | 689,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | 29,598,000Source | 29,598,000Source | — | — | 26,438,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 25,700,000Source | 44,400,000Source | 182,200,000Source | 165,000,000Source | 137,400,000Source | 130,793,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 45,000Source | 165,000Source | 347,000Source | 347,000Source | 283,000Source | 2,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -30,255,000Source | -26,357,000Source | -40,965,000Source | -31,440,000Source | -38,990,000Source | -28,435,000Source | -123,547,000Source | -103,196,000Source | -60,007,000Source | -38,839,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 694,000Source | 2,109,000Source | 737,000Source | 1,039,000Source | 1,706,000Source | 1,796,000Source | 4,710,000Source | 7,315,000Source | 5,309,000Source | 689,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | -26,639,000Source | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 9,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,561,000Source | -24,248,000Source | -40,228,000Source | -30,401,000Source | -37,284,000Source | -26,639,000Source | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.14Source | -0.11Source | -0.16Source | -0.14Source | -0.15Source | -0.12Source | -0.53Source | -0.48Source | -0.33Source | -0.25Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.14Source | -0.11Source | -0.16Source | -0.14Source | -0.15Source | -0.12Source | -0.53Source | -0.48Source | -0.33Source | -0.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 216,462,161Source | 211,847,651Source | 253,569,891Source | 216,431,348Source | 253,280,551Source | 216,146,934Source | 222,387,531Source | 198,191,936Source | 165,204,652Source | 152,771,817Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 216,462,161Source | 211,847,651Source | 253,569,891Source | 216,431,348Source | 253,280,551Source | 216,146,934Source | 222,387,531Source | 198,191,936Source | 165,204,652Source | 152,771,817Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 9,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 36,000Source | 33,000Source | 28,000Source | 34,000Source | 24,000Source | 30,000Source | 87,000Source | 130,000Source | 77,000Source | 31,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 146,000Source | -20,000Source | -81,000Source | 118,000Source | -216,000Source | 60,000Source | 310,000Source | 51,000Source | 76,000Source | -19,000Source |
| General and Administrative ExpenseUSD | — | — | 9,627,000Source | 6,013,000Source | 18,986,000Source | 10,655,000Source | 15,568,000Source | 9,246,000Source | 42,056,000Source | 25,037,000Source | 15,668,000Source | 10,929,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -84,300,000Source | -63,256,000Source | -40,834,000Source | -29,326,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 548,000Source | 2,129,000Source | 829,000Source | 921,000Source | 1,057,000Source | 1,498,000Source | 4,162,000Source | 6,467,000Source | 4,436,000Source | -88,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -29,561,000Source | -24,248,000Source | -40,228,000Source | -30,401,000Source | -37,284,000Source | -26,639,000Source | -118,837,000Source | -95,881,000Source | -54,698,000Source | -38,150,000Source |
| Operating ExpensesUSD | — | — | 30,255,000Source | 26,357,000Source | 40,965,000Source | 31,440,000Source | 38,990,000Source | 28,435,000Source | 123,547,000Source | 103,196,000Source | 60,007,000Source | 38,839,000Source |
Filing attachments
svra-ex4_19.htm · 10-K · 2026-03-13
Exhibit 4.19 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description of registered securities of Savara Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation, our amended and restated bylaws and applicable provisions o…
Read attachment ↗svra-ex4_22.htm · 10-K · 2026-03-13
Exhibit 4.22 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: October [●], 2025 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Holder”), is entitled, subject to the terms …
Read attachment ↗d24211dex991.htm · 8-K · 2026-01-09
Corporate Overview January 2026 Developing new therapies for rare respiratory diseases Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited…
Read attachment ↗d62228dex41.htm · 8-K · 2025-10-30
EX-4.1 3 d62228dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: October 31, 2025 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Ho…
Read attachment ↗d62228dex991.htm · 8-K · 2025-10-30
EX-99.1 5 d62228dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pa., October 29, 2025 - Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so ch…
Read attachment ↗d55049dex991.htm · 8-K · 2025-10-29
EX-99.1 2 d55049dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES $75M ROYALTY FUNDING AGREEMENT WITH RTW TO SUPPORT THE POTENTIAL LAUNCH OF MOLBREEVI* IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) - RTW Committed $75M in Launch Funding, Subject to U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - - Royalties Based on Annual Net Sales of MOLBREEVI in the U.S. - - Funds Will Strengthen the Company’s Balance Sheet for Potential U.S. Commercialization…
Read attachment ↗